Pharma & drug development · Reference
What is a New Drug Application (NDA)?
A New Drug Application (NDA) is the formal request a company submits to the FDA to approve a new drug for marketing in the United States. It assembles all the evidence from discovery and clinical testing into one comprehensive package for review.
What an NDA contains
An NDA is intended to tell the drug’s whole story. It brings together the preclinical pharmacology and toxicology data, the results of the Phase 1, 2 and 3 clinical trials conducted under Good Clinical Practice, the proposed labelling describing how the drug should be used, and detailed chemistry, manufacturing and controls information showing the product can be made consistently under Good Manufacturing Practice. The aim is to give the FDA everything it needs to assess safety, effectiveness and quality in a single, structured dossier.
Where the NDA sits in the pathway
The NDA is the culmination of the FDA approval process. A candidate first clears an Investigational New Drug application, then progresses through the clinical phases; only when those trials are complete is the evidence compiled into the NDA. For a biological product, the equivalent submission is a Biologics License Application (BLA) rather than an NDA. The NDA therefore marks the transition from generating evidence to formally seeking permission to market, and it is the document on which the approval decision turns.
How the FDA reviews it
Once filed, the NDA is examined by FDA review teams covering medical, statistical, pharmacological, chemistry and labelling disciplines. They weigh whether the demonstrated benefits outweigh the risks for the proposed use, and may convene an advisory committee for outside expert input. The agency can approve the application, issue a letter requesting more information, or decline it.
Approval of an NDA authorises marketing for the specified use, but it does not end oversight: post-market pharmacovigilance continues, and the agency can require label changes or further studies. This describes a regulatory submission and review process at an educational level and is not advice about using any specific medicine.
Key facts
At a glance
- Definition: Formal FDA request to market a new drug
- Submitted by: The drug’s sponsor (company)
- Contains: Preclinical, clinical, labelling, manufacturing data
- Biologic equivalent: Biologics License Application (BLA)
- Reviewed by: FDA multidisciplinary review teams
- Outcome: Approval, request for more data, or refusal
Common questions
FAQ
What is a New Drug Application?+
A New Drug Application is the formal package a company submits to the FDA asking it to approve a new drug for marketing. It gathers the preclinical, clinical, labelling and manufacturing evidence into one dossier for review. This is an educational description of a regulatory filing, not medical advice.
What is the difference between an NDA and a BLA?+
An NDA is the marketing application for a conventional small-molecule drug, while a Biologics License Application (BLA) is the equivalent for a biological product such as a vaccine or monoclonal antibody. Both are reviewed by the FDA before approval.
What happens after an NDA is submitted?+
FDA review teams assess the safety, effectiveness and quality evidence, sometimes with input from an advisory committee, and then approve the application, ask for more information, or decline it. Approval permits marketing for the stated use while post-market monitoring continues.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
